Type 1 inflammation pathway (T1 inflammation)

Type 1 inflammation is a coordinated immune response primarily designed to eliminate intracellular pathogens, such as viruses and certain bacteria, and to provide surveillance against malignant cells (Annunziato et al., 2015, PMID: 25470324). This pathway is characterized by the differentiation of T helper 1 (Th1) cells and the activation of natural killer (NK) cells and macrophages, driven largely by cytokines such as interleukin-12 (IL-12) and interferon-gamma (IFN-gamma) (Abbas et al., 2021). While protective in a healthy state, overactivation of Type 1 pathways leads to tissue destruction and is a hallmark of several autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and multiple sclerosis (StatPearls, 2023). Pharmacological intervention typically involves monoclonal antibodies that neutralize effector cytokines like TNF-alpha or IFN-gamma, or small molecules that inhibit intracellular signaling through the Janus kinase (JAK) family (O'Shea et al., 2013, PMID: 23348502). Balancing the suppression of this pathway is critical, as excessive inhibition can predispose patients to serious infections, such as tuberculosis, and potentially impair tumor immunosurveillance (Rubbert-Feld et al., 2021, PMID: 33558245).

Other names

Th1 responseType 1 immunityCell-mediated immune responseTh1-mediated inflammation

Inhibition of Type 1 cytokines (IFN-gamma, IL-12, TNF-alpha) or their downstream signaling components (JAK1, JAK2, STAT1) to suppress cell-mediated inflammatory responses.